USFDA grants Breakthrough Designation to Datar Cancer Genetics for its prostate cancer detection blood test

It is the first blood test able to detect early-stage Prostate Cancer with high accuracy in men aged 55 years and above

Datar Cancer Genetics has announced that the US Food and Drug Administration (FDA) has granted ‘Breakthrough Designation’ for its blood test to detect early-stage prostate cancer.

The test is available in India by the name of Easycheck. Men with serum PSA of more than 3 ng/mL can avail of this test in consultation with their physician.

The test requires 5 ml blood and does not involve exposure to radiation or any of the discomforts of a digital rectal examination. The blood test is based on the detection of Circulating Tumor Cells (CTCs) specific to prostate adenocarcinoma.

The test is already available in Europe and is CE marked. The company is in discussions with several healthcare providers for ready accessibility in India.